You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国药中生:「武汉造」新冠灭活疫苗二期扩产项目投产
阿思达克 06-01 08:41
国药集团中国生物武汉生物制品研究所新冠灭活疫苗二期扩产项目投产活动昨日(5月31日)在武汉举行。国药集团董事长刘敬桢在致辞中表示,武汉生物制品研究所新冠灭活疫苗二期扩产项目仅用不到三个月的时间,完成建设并具备投产条件。

该项目仅用86天顺利建成并投产,投产後年产能可达10亿剂,中国生物新冠疫苗年产能将大幅提升。

据悉,中国生物武汉生物制品研究所与中科院武汉病毒研究所合作研发的新冠病毒灭活疫苗於2021年2月25日获批附条件上市,新冠灭活疫苗一期车间投入规模化生产,年产能约1亿剂次。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account